Abstract
Background Different regions of the brain’s grey matter are connected by a complex structural network of white-matter fibres, which are responsible for the propagation of action potentials and the transport of trophic and other molecules. In neurodegenerative disease, these connections constrain the way in which grey-matter volume change progresses. Here we investigated whether connectome architecture also shapes the spatial pattern of longitudinal grey matter volume changes attributable to illness and antipsychotic medication in first episode psychosis (FEP).
Methods We conducted a triple-blind randomised placebo-control MRI study where 62 young adults with FEP received either an atypical antipsychotic or placebo over 6-months. Anatomical MRI scans were acquired at baseline, 3 months, and 12 months. Deformation-based morphometry was used to estimate illness-related and antipsychotic-related volume changes over time. Representative functional and structural brain connectivity patterns were derived from an independent healthy control group using resting-state functional MRI and diffusion-weighted imaging. We used neighbourhood deformation models to predict the extent of brain change in each of 332 parcellated areas by the changes observed in areas to which the index region is either structurally connected or functionally coupled.
Results At baseline, we found that empirical illness-related regional volume differences were robustly correlated with predicted differences using a model constrained by structural connectivity weights (r = .54; p < .001). At 3 months and 12 months, we also found a robust correlation between longitudinal regional illness-related (r > .52; p < .001) and antipsychotic-related volume change (r >.59; p < .001) with volumetric changes in structurally connected areas. These correlations were significantly greater than those observed across various null models accounting for lower-order spatial and network properties of the data. Associations between empirical and predicted volume-change estimates were much lower for models that only considered binary structural connectivity (all r < .37), or which were constrained by inter-regional functional coupling (all r < .43). Finally, we found that epicentres of volume change emerged posteriorly early in the illness and shifted to the prefrontal cortex by later illness stages.
Conclusion Psychosis- and antipsychotic-related grey-matter volume changes are strongly shaped by structural brain connectivity. This result is consistent with findings in other neurological disorders and implies that such connections may constrain pathological processes causing brain dysfunction in FE
Competing Interest Statement
SF, KA, MAJ and AF reported receiving grants from the Australian National Health & Medical Research Council (NHMRC) during the conduct of the study. CP reported receiving grants from the Australian NHMRC and from the Lundbeck Foundation and personal fees from Lundbeck Australia Pty Ltd Advisory Board for talks presented at educational meetings organized by Lundbeck. PM reported receiving grants from the Australian NHMRC, the Colonial Foundation, the National Alliance for Research on Schizophrenia and Depression, the Stanley Foundation, the National Institutes of Health, Wellcome Trust, the Australian and Victorian governments, and Janssen-Cilag (unrestricted investigator-initiated grant) during the conduct of the study; past unrestricted grant funding from Janssen-Cilag, AstraZeneca, Eli Lilly, Novartis, and Pfizer; honoraria for consultancy and teaching from Janssen-Cilag, Eli Lilly, Pfizer, AstraZeneca, Roche, Bristol Myers Squibb, and Lundbeck. BN was supported by an NHMRC Senior Research Fellowship (1137687) and a University of Melbourne Dame Kate Campbell Fellowship. This work was supported by the computational infrastructure provided by the MASSIVE HPC facility (www.massive.org.au).
Clinical Trial
ACTRN12607000608460
Funding Statement
Janssen-Cilag partially supported the early years of the clinical trial dataset used in this study, with an unrestricted investigator-initiated grant and provided risperidone, paliperidone and matched placebo for the first 30 participants. The study was then funded by an Australian National Health and Medical Research Project grant (1064704). The funders had no role in study design, data collection, data analysis, data interpretation, writing, approval, or submission of this manuscript. SC and AF had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Melbourne Health Human Research Ethics Committee (MHREC:2007.616) Monash University Human Research Ethics Committee (MUHREC: 2012001562)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Link to GitHub repository added.
Data Availability
All code and group-level data used in the study are available online at https://github.com/sidchop/NetworkDeformationModels Individual/patient level data may be made available upon reasonable request to the authors
